CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Current Features

Advertisement

Current Edition

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Advertisement

Solstice
Current Features

Evolving Quality Risk Management: A Deep Dive into ICH Q9 (R1) with Kevin O’Donnell (HPRA) on the Pharma Conversations Podcast

In a recent episode of the Pharma Conversations podcast, Kevin O’Donnell of the Health Products Regulatory Authority (HPRA) offered a detailed and thought-provoking ...
Continue Reading →
Current Features

Solstice Advanced Materials on Powering the Global Shift to Low-GWP Inhaler Propellants

Solstice Advanced Materials outlines its perspective on the transition to lowGWP propellants in an interview with International Pharmaceutical Industry Journal, ...
Continue Reading →
Current Features

Terumo Pharmaceutical Solutions on Integrated CDMO Services

International Pharmaceutical Industry Journal speaks with Michele Guasti, Global Product Manager at Terumo Pharmaceutical Solutions Division. The discussion explores...
Continue Reading →
Current Features

PFAS and Pharmaceuticals: Why the Industry Can No Longer Afford to Wait

Few regulatory issues have the potential to reshape pharmaceutical manufacturing as profoundly as PFAS. Often referred to as "forever chemicals", per- and polyfluoro...
Continue Reading →
Current Features

Differences Between US and EU Pre- and Post-Market Regulatory Obligations

Typically, global companies developing innovative therapies are familiar with the differences between regulatory systems in the United States and European Union. In ...
Continue Reading →
Current Features

Why Predictive Analytics are Crucial for Effective EU-HTAR Implementation

The EU’s Health Technology Assessment Regulation (EU-HTAR) aims to introduce more harmonised, efficient and evidencebased assessments of new health technologies. How...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026

Company Profiles